Last reviewed · How we verify
Chemotherapy,Gemcitabine based regimen
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis in rapidly dividing cancer cells.
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis in rapidly dividing cancer cells. Used for Gemcitabine-based regimen for solid tumors (specific indication under investigation in phase 3 trial at Eye & ENT Hospital of Fudan University, likely head and neck or related malignancies).
At a glance
| Generic name | Chemotherapy,Gemcitabine based regimen |
|---|---|
| Sponsor | Eye & ENT Hospital of Fudan University |
| Drug class | Nucleoside analog; antimetabolite chemotherapy |
| Target | Ribonucleotide reductase; DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a deoxycytidine analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase, an enzyme essential for deoxyribonucleotide production. Once incorporated into DNA during replication, it causes chain termination and triggers apoptosis. It is particularly effective against cells with high proliferation rates, making it useful in various solid tumors.
Approved indications
- Gemcitabine-based regimen for solid tumors (specific indication under investigation in phase 3 trial at Eye & ENT Hospital of Fudan University, likely head and neck or related malignancies)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Fatigue
- Elevated liver enzymes
- Rash
- Hemolytic uremic syndrome (rare)
Key clinical trials
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (PHASE3)
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors (NA)
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: